Venus Remedies bags DCGI approval for launch of its one more R&D product

Venus Remedies Ltd has announced that the Drug Controller General of India has granted its approval to the Company for launch of its third innovative R&D developed product, Fixed Dose Combination Drug of latest generation Cephalosporin with an Amino-glycoside, after completion of its Clinical Trials and all related studies. This Premium Product shall launched for the first time in the World, in India very shortly by the Company.

This new FDC shall be launched under Strategic Marketing tie-up with leading Indian Pharma Companies, in the Rs 4.00 billion domestic market and is expected to gain a substantial share in the market within the very first year of its launch. The Company´s plans to take this Product to the International market are also being pursued aggressively.

The commercial launch of this product shall help the millions of patients across India to recover fast with this sure shot remedy for Hospital acquired Pneumonia (HAP), which has acquired alarming proportions through out the world, and the treatment time shall also be reduced to almost 50% what it is at present.

The Company has already filed Patent applications for worldwide protection of its Patent rights.

Source : Equity Bulls

Keywords